A plasminogen activator inhibitor-1 inhibitor reduces airway remodeling in a murine model of chronic asthma

American Journal of Respiratory Cell and Molecular Biology

Volumn 46, Issue 6, 2012, Pages 842-846

  Lee, Sun H ^a   Eren, Mesut ^a   Vaughan, Douglas E ^a   Schleimer, Robert P ^a   Cho, Seong H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Airway remodeling; Asthma; Collagen deposition; Plasminogen activator inhibitor 1; Tiplaxtinin

Indexed keywords

COLLAGEN; METHACHOLINE; OVALBUMIN; PHOSPHATE BUFFERED SALINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TIPLASININ;

AIRWAY REMODELING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; BODY PLETHYSMOGRAPHY; BRONCHUS HYPERREACTIVITY; CELL HYPERPLASIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; GOBLET CELL; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LUNG LAVAGE; LUNG PARENCHYMA; MOUSE; NEBULIZATION; NONHUMAN; TREATMENT RESPONSE;

ANIMALS; ASTHMA; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C57BL; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMALIA; MURINAE; MUS;

EID: 84861772744     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2011-0369OC     Document Type: Article

References (22)

1. Orihara K, Dil N, Anaparti V, Moqbel R. What's new in asthma pathophysiology and immunopathology? Expert Rev Respir Med 2010;4: 605-629.
2. Shum BO, Rolph MS, Sewell WA. Mechanisms in allergic airway inflammation-lessons from studies in the mouse. Expert Rev Mol Med 2008;27:10-15.
3. Beier JI, Kaiser JP, Guo L, Martinez-Maldonado M. Plasminogen activator inhibitor-1 deficient mice are protected from angiotensin II-induced fibrosis. Arch Biochem Biophys 2011;510:19-26.
4. Brown NJ. Therapeutic potential of plasminogen activator inhibitor-1 inhibitors. Ther Adv Cardiovasc Dis 2010;4:315-324.
5. Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brünner N, Foekens J, Harbeck N, Schmitt M. Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2010;10:947-962.
6. Oh CK, Ariue B, Alban RF, Shaw B, Cho SH. PAI-1 promotes extra-cellular matrix deposition in the airways of a murine asthma model. Biochem Biophys Res Commun 2002;294:1150-1160.
7. Cho SH, Hall IP, Wheatley A, Dewar J, Abraha D, Del MJ, Lee H, Oh CK. Possible role of the 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene in the development of asthma. J Allergy Clin Immunol 2001;108:212-214. (Pubitemid 32735403)
8. Cho SH, Kang J, Lyttle C, Harris K, Daley B, Grammer L, Avila P, Kumar R, Schleimer R. Association of elevated plasminogen activator inhibitor 1 levels with diminished lung function in patients with asthma. Ann Allergy Asthma Immunol 2011;106:371-377.
9. Xio W, Hsu YP, Ishizaka A, Kirikae T, Moss RB. Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. Chest 2005;128:2316-2326. (Pubitemid 41507575)
10. Miyamoto S, Hattori N, Senoo T, Onari Y, Lwamoto H, Kanehara M, Ishikawa N, Fusitaka K, Haruta Y, Murai H, et al. Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 attenuates allergic asthma in mice. Am J Physiol Lung Cell Mol Physiol 2011;301:L908-L916.
11. Olmez D, Babayigit A, Uzuner N, Erbil G, Karaman O, Yilmaz O, Cetin EO, Ozogul C. Efficacy of sulphasalazine on lung histopathology in a murine model of chronic asthma. Exp Lung Res 2008;34:501-511.
12. Munroe ME, Businga TR, Kline JN, Bishop GA. Anti-inflammatory effects of the neurotransmitter agonist Honokiol in a mouse model of allergic asthma. J Immunol 2010;185:5586-5597.
13. Lundequist A, Nallamshetty SN, Xing W, Feng C, Laidlaw TM, Uematsu S, Akira S, Boyce JA. Prostaglandin E(2) exerts homeostatic regulation of pulmonary vascular remodeling in allergic airway inflammation. J Immunol 2010;184:433-441.
14. Liu SY, Wang WZ, Yen CL, Tsai MY, Yang PW, Wang JY, Ho CY, Shieh CC. Leukocyte nicotinamide adenine dinucleotide phosphate-reduced oxidase is required for isocyanate-induced lung inflammation. J Allergy Clin Immunol 2011;127:1014-1023.
15. Crandall DL, Quinet EM, El AS, Hreha AL, Leik CE, Savio DA, Vague IJ, Alessi MC. Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol 2006; 26:2209-2215. (Pubitemid 44465713)
16. Lijnen HR, Alessi MC, Van Hoef B, Collen D, Juhan-Vague I. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost 2005;6:1174-1179. (Pubitemid 41725239)
17. Hennan JK, Morgan GA, Swillo RE, Antrilli TM, Mugford C, Vlasuk GP. Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J Thromb Haemost 2008;6: 1558-1564.
18. Smith LH, Dixon JD, Stringham JR, Eren M, Elokdah H, Crandall DL, Washington K, Vaughan DE. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 2006;107:132-134. (Pubitemid 43053534)
19. Sejima T, Madoiwa S, Mimuro J, Sugo T, Okada K, Ueshima S, Matsuo O, Ishida T, Ichimura K, Sakata Y. Protection of plasminogen activator inhibitor-1-deficient mice from nasal allergy. J Immunol 2005; 174:8135-8143. (Pubitemid 40806325)
20. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma: from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161:1720-1745. (Pubitemid 30329053)
21. Adcock IM, Ford PA, Bhavsar P, Ahmad T, Chung KF. Steroid resistance in asthma: mechanisms and treatment options. Curr Allergy Asthma Rep 2008;8:171-178. (Pubitemid 351524105)
22. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992;90:32-42.